Page 948 - Read Online

Caron de Fromentel et al. Hepatoma Res 2020;6:80 I http://dx.doi.org/10.20517/2394-5079.2020.77 Page 17 of 18

133. Siddique HR, Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences.
Stem Cells 2012;30:372-8.
134. Meier C, Hardtstock P, Joost S, Alla V, Pützer BM. p73 and IGF1R regulate emergence of aggressive cancer stem-like features via miR-
885-5p Control. Cancer Res 2016;76:197-205.
135. Niemantsverdriet M, Nagle P, Chiu RK, et al. ΔNp73 enhances promoter activity of TGF-β induced genes. PLoS One 2012;7:e50815.
136. Alexandrova EM, Petrenko O, Nemajerova A, et al. ΔNp63 regulates select routes of reprogramming via multiple mechanisms. Cell
Death Differ 2013;20:1698-708.
137. Martin-Lopez M, Maeso-Alonso L, Fuertes-Alvarez S, et al. p73 is required for appropriate BMP-induced mesenchymal-to-epithelial
transition during somatic cell reprogramming. Cell Death Dis 2017;8:e3034.
138. Lin Y, Cheng Z, Yang Z, Zheng J, Lin T. DNp73 improves generation efficiency of human induced pluripotent stem cells. BMC Cell Biol
2012;13:9.
139. Ramalho FS, Ramalho LN, Della Porta L, Zucoloto S. Comparative immunohistochemical expression of p63 in human
cholangiocarcinoma and hepatocellular carcinoma. J Gastroenterol Hepatol 2006;21:1276-80.
140. Petitjean A, Cavard C, Shi H, et al. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells. Oncogene
2005;24:512-9.
141. Lanza M, Marinari B, Papoutsaki M, et al. Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and
p53 gain-of-function mutants. Cell Cycle 2006;5:1996-2004.
142. Ruptier C, De Gaspéris A, Ansieau S, et al. TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63
expression. Oncogene 2011;30:4656-65.
143. Petitjean A, Ruptier C, Tribollet V, et al. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and
cross talk with ΔNp73. Carcinogenesis 2008;29:273-81.
144. Stiewe T, Tuve S, Peter M, et al. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004;10:626-33.
145. Castillo J, Goñi S, Latasa MU, et al. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in
human hepatocellular tumors. Gastroenterology 2009;137:1805-15.e1-4.
146. Müller M, Schilling T, Sayan AE, et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in
hepatocellular carcinoma. Cell Death Differ 2005;12:1564-77.
147. Schuster A, Schilling T, De Laurenzi V, et al. ΔNp73β is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death
receptors and mitochondria. Cell Cycle 2010;9:2629-39.
148. Zhao L, Fu L, Xu Z, et al. The anticancer effects of cinobufagin on hepatocellular carcinoma Huh-7 cells are associated with activation of
the p73 signaling pathway. Mol Med Rep 2019;19:4119-28.
149. Yoon MK, Ha JH, Lee MS, Chi SW. Structure and apoptotic function of p73. BMB Rep 2015;48:81-90.
150. González R, De la Rosa ÁJ, Rufini A, et al. Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma
submitted to orthotopic liver transplantation. PLoS One 2017;12:e0174326.
151. Gifu P, Pez F, Bian L, et al. DeltaNp73 isoforms are involved in the immature phenotype of liver cancer cells. J Hepatol 2017;66:S646.
152. Akita H, Marquardt JU, Durkin ME, et al. MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism.
Cancer Res 2014;74:5903-13.
153. Li H, Wolfe A, Septer S, et al. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int 2012;32:38-47.
154. Tschaharganeh DF, Xue W, Calvisi DF, et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver
cancer. Cell 2014;158:579-92.
155. Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and
cholangiocytic differentation. Hepatology 2018;68:113-26.
156. Machida K. Existence of cancer stem cells in hepatocellular carcinoma: myth or reality? Hepatol Int 2017;11:143-7.
157. Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma. Hepatology 2009;49:318-29.
158. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013;123:1911-8.
159. Wu Y, Zhang J, Zhang X, et al. Cancer stem cells: a potential breakthrough in HCC-targeted therapy. Front Pharmacol 2020;11:198.
160. Li XF, Chen C, Xiang DM, et al. Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical
significance. Hepatology 2017;66:1934-51.
161. Dubois-Pot-Schneider H, Fekir K, Coulouarn C, et al. Inflammatory cytokines promote the retrodifferentiation of tumor-derived
hepatocyte-like cells to progenitor cells. Hepatology 2014;60:2077-90.
162. Belloni L, Di Cocco S, Guerrieri F, et al. Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro
and in vivo model. Sci Rep 2018;8:13638.
163. Pediconi N, Salerno D, Lupacchini L, et al. EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-
differentiation and proliferation of liver cells. Cell Death Dis 2019;10:518.
164. Li M, He Y, Dubois W, et al. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response
genes in embryonic stem cells. Mol Cell 2012;46:30-42.
165. Young RA. Control of the embryonic stem cell state. Cell 2011;144:940-54.
166. Yin X, Li YW, Zhang BH, et al. Coexpression of stemness factors Oct4 and Nanog predict liver resection. Ann Surg Oncol 2012;19:2877-
87.
167. Zhao X, Sun B, Sun D, et al. Slug promotes hepatocellular cancer cell progression by increasing sox2 and nanog expression. Oncol Rep
2015;33:149-56.